Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study
- PMID: 18495537
- DOI: 10.1016/S1470-2045(08)70132-3
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study
Abstract
Background: In the USA, about 30 200 well-differentiated thyroid carcinomas were diagnosed in 2007, but the prevalence of thyroid nodules is much higher (about 5% of the adult population). Unfortunately, the preoperative characterisation of follicular thyroid nodules is still a challenge, and many benign lesions, which remain indeterminate after fine-needle aspiration (FNA) cytology are referred to surgery. About 85% of these thyroid nodules are classified as benign at final histology. We aimed to assess the diagnostic effect of galectin-3 expression analysis in distinguishing preoperatively benign from malignant follicular thyroid nodules when FNA findings were indeterminate.
Methods: 544 patients were enrolled between June 1, 2003, and Aug 30, 2006. We used a purified monoclonal antibody to galectin-3, a biotin-free immunocytohistochemical assay, and a morphological and phenotypic analysis of FNA-derived cell-block preparations. Galectin-3-expression analysis was applied preoperatively on 465 follicular thyroid proliferations that were candidates for surgery, and its diagnostic accuracy was compared with the final histology.
Findings: 31 patients were excluded because they had small galectin-3-negative thyroid nodules; we did not have data for 47 patients; and one patient with an oncocytic nodule was excluded. 331 (71%) of the assessable 465 preoperative thyroid FNA samples did not express galectin-3. 280 (85%) of these galectin-3-negative lesions were classified as benign at final histology. Galectin-3 expression was detected, instead, in 134 of 465 (29%) thyroid proliferations, 101 (75%) of which were confirmed as malignant. The overall sensitivity of the galectin-3 test was 78% (95% CI 74-82) and specificity was 93% (90-95). Estimated positive predictive value was 82% (79-86) and negative predictive value was 91% (88-93). 381 (88%) of 432 patients with follicular thyroid nodules who were referred for thyroidectomy were correctly classified preoperatively by use of the galectin-3 test. However, 29 (22%) of 130 cancers were missed by the galectin-3 method.
Interpretation: Our findings show that if the option of surgery was based theoretically on galectin-3 expression alone, only 134 thyroid operations would have been done in 465 patients; therefore a large proportion (71%) of unnecessary thyroid surgical procedures could be avoided, although a number of galectin-3-negative cancers could be potentially missed. The galectin-3 test proposed here does not replace conventional FNA cytology, but represents a complementary diagnostic method for those follicular nodules that remain indeterminate.
Comment in
-
Galectin-3 for indeterminate thyroid cytology.Lancet Oncol. 2008 Jun;9(6):508-10. doi: 10.1016/S1470-2045(08)70137-2. Lancet Oncol. 2008. PMID: 18510984 No abstract available.
Similar articles
-
Galectin-3 for indeterminate thyroid cytology.Lancet Oncol. 2008 Jun;9(6):508-10. doi: 10.1016/S1470-2045(08)70137-2. Lancet Oncol. 2008. PMID: 18510984 No abstract available.
-
Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.Br J Cancer. 2006 Jul 17;95(2):204-9. doi: 10.1038/sj.bjc.6603232. Epub 2006 Jun 27. Br J Cancer. 2006. PMID: 16804521 Free PMC article.
-
Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing.Cancer Cytopathol. 2015 Aug;123(8):471-9. doi: 10.1002/cncy.21554. Epub 2015 Apr 27. Cancer Cytopathol. 2015. PMID: 25924719
-
Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.Cytopathology. 2013 Dec;24(6):385-90. doi: 10.1111/cyt.12021. Epub 2012 Oct 18. Cytopathology. 2013. PMID: 23078633 Review.
-
Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules.Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):2-7. doi: 10.1097/PAI.0b013e31821ee9bb. Appl Immunohistochem Mol Morphol. 2012. PMID: 21691201 Review.
Cited by
-
Malignancy risk assessment in patients with thyroid nodules using classification and regression trees.J Thyroid Res. 2013;2013:983953. doi: 10.1155/2013/983953. Epub 2013 Sep 11. J Thyroid Res. 2013. PMID: 24102036 Free PMC article.
-
Diagnostic performance of elastography in cytologically indeterminate thyroid nodules.Endocrine. 2015 May;49(1):175-83. doi: 10.1007/s12020-014-0438-0. Epub 2014 Oct 2. Endocrine. 2015. PMID: 25273318
-
Molecular approaches to thyroid cancer diagnosis.Endocr Relat Cancer. 2014 Oct;21(5):T301-13. doi: 10.1530/ERC-14-0166. Epub 2014 May 14. Endocr Relat Cancer. 2014. PMID: 24829266 Free PMC article. Review.
-
Molecular pathology of thyroid cancer: diagnostic and clinical implications.Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):955-69. doi: 10.1016/j.beem.2008.09.017. Best Pract Res Clin Endocrinol Metab. 2008. PMID: 19041825 Free PMC article. Review.
-
Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules.Endocrine. 2016 Oct;54(1):139-147. doi: 10.1007/s12020-015-0774-8. Epub 2015 Oct 16. Endocrine. 2016. PMID: 26475496
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical